NYSE:CBM - Cambrex Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$37.60 -0.34 (-0.90 %)
(As of 04/18/2019 10:31 AM ET)
Previous Close$37.93
Today's Range$37.5950 - $38.47
52-Week Range$33.80 - $69.43
Volume16,099 shs
Average Volume390,777 shs
Market Capitalization$1.27 billion
P/E Ratio13.57
Dividend YieldN/A
Beta2.4
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

Receive CBM News and Ratings via Email

Sign-up to receive the latest news and ratings for CBM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP13201110
Phone201-804-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$532.09 million
Cash Flow$3.8284 per share
Book Value$19.48 per share

Profitability

Net Income$92.41 million

Miscellaneous

Employees1,732
Market Cap$1.27 billion
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable

Cambrex (NYSE:CBM) Frequently Asked Questions

What is Cambrex's stock symbol?

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

How were Cambrex's earnings last quarter?

Cambrex Co. (NYSE:CBM) posted its quarterly earnings data on Wednesday, February, 13th. The biotechnology company reported $1.44 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.32 by $0.12. The biotechnology company had revenue of $212.30 million for the quarter, compared to analysts' expectations of $182.49 million. Cambrex had a net margin of 17.37% and a return on equity of 14.74%. Cambrex's revenue for the quarter was up 16.5% compared to the same quarter last year. During the same period in the prior year, the business earned $1.26 earnings per share. View Cambrex's Earnings History.

When is Cambrex's next earnings date?

Cambrex is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Cambrex.

What guidance has Cambrex issued on next quarter's earnings?

Cambrex updated its FY19 earnings guidance on Wednesday, February, 13th. The company provided EPS guidance of $1.87-2.09 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.18. Cambrex also updated its FY 2019 guidance to $1.87-2.09 EPS.

What price target have analysts set for CBM?

4 brokerages have issued 12 month price targets for Cambrex's shares. Their predictions range from $43.00 to $63.00. On average, they expect Cambrex's stock price to reach $50.3333 in the next twelve months. This suggests a possible upside of 33.9% from the stock's current price. View Analyst Price Targets for Cambrex.

What is the consensus analysts' recommendation for Cambrex?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 1 hold rating, 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cambrex.

Has Cambrex been receiving favorable news coverage?

Media stories about CBM stock have been trending somewhat positive this week, InfoTrie reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cambrex earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days.

Who are some of Cambrex's key competitors?

What other stocks do shareholders of Cambrex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cambrex investors own include Celgene (CELG), Illumina (ILMN), AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), CVS Health (CVS), Gilead Sciences (GILD), Juno Therapeutics (JUNO), QUALCOMM (QCOM) and Western Digital (WDC).

Who are Cambrex's key executives?

Cambrex's management team includes the folowing people:
  • Mr. Steven M. Klosk, Pres, CEO & Director (Age 62)
  • Mr. Gregory P. Sargen, Exec. VP of Corp. Devel. & Strategy and CFO (Age 53)
  • Mr. Shawn P. Cavanagh, Exec. VP & COO (Age 53)
  • Ms. Samantha M. Hanley, VP, Gen. Counsel & Corp. Sec. (Age 41)
  • Mr. James G. Farrell, VP & Corp. Controller (Age 52)

Who are Cambrex's major shareholders?

Cambrex's stock is owned by a number of of institutional and retail investors. Top institutional investors include Tributary Capital Management LLC (1.07%), Summit Creek Advisors LLC (0.67%), Peregrine Capital Management LLC (0.59%), Confluence Investment Management LLC (0.32%), Scout Investments Inc. (0.26%) and Campbell Newman Asset Management Inc. (0.04%). Company insiders that own Cambrex stock include Gregory Sargen, Ilan Kaufthal, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Institutional Ownership Trends for Cambrex.

Which institutional investors are selling Cambrex stock?

CBM stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., Peregrine Capital Management LLC and Summit Creek Advisors LLC. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Ilan Kaufthal, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Insider Buying and Selling for Cambrex.

Which institutional investors are buying Cambrex stock?

CBM stock was acquired by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, Confluence Investment Management LLC, Nisa Investment Advisors LLC, Flagship Harbor Advisors LLC and Campbell Newman Asset Management Inc.. View Insider Buying and Selling for Cambrex.

How do I buy shares of Cambrex?

Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cambrex's stock price today?

One share of CBM stock can currently be purchased for approximately $37.5950.

How big of a company is Cambrex?

Cambrex has a market capitalization of $1.27 billion and generates $532.09 million in revenue each year. The biotechnology company earns $92.41 million in net income (profit) each year or $2.77 on an earnings per share basis. Cambrex employs 1,732 workers across the globe.

What is Cambrex's official website?

The official website for Cambrex is http://www.cambrex.com.

How can I contact Cambrex?

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]


MarketBeat Community Rating for Cambrex (NYSE CBM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  242 (Vote Outperform)
Underperform Votes:  231 (Vote Underperform)
Total Votes:  473
MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe CBM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel